Latest news with #DiabetesMellitus
Mint
a day ago
- General
- Mint
COVID-19 update, 4 June 2025: 7 new deaths in India over last 24 hours, active toll jumps over 4,300 — latest updates
COVID-19 news, 4 June updates: The Ministry of Health and Family Welfare (MoH&FW) data shows that seven people have lost their lives, and the nation's active COVID-19 cases now stand at 4,302 as of 5 June 2025. The daily updating database also highlighted that 276 new COVID-19 cases have been added to the official numbers as of Wednesday. The Ministry data sheds light on 44 people losing their lives to the global pandemic, which made a recent comeback in India. 1. Delhi: The national capital reported the death of one, 22-year-old female who lost her life due to lower respiratory tract infection, COVID pneumonia, shock and Type 1 respiratory failure. 2. Maharashtra: The State reported four deaths in the last 24 hours, with the first one a 55-year-old man with Cardiac Arrythmia and was on antiarrythimics. The second person was a 73-year-old male with Cardiogenic Shock, Parkinson's Disease, COVID-19 pneumonia, and Hypertension. The third person who lost their life was a 23-year-old female with Diabetes Mellitus and HTN. The fourth death was of a 27-year-old male with IHD with old PTB, LRTI, and alcohol withdrawal seizure. 3. Tamil Nadu: The State reported one death in the last 24 hours, a 76-year-old male with Acute Respiratory Distress Syndrome (ARDS), COVID-19 pneumonia, and sepsis with multi-organ dysfunction syndrome (MODS). 4. Gujarat: The State reported one death without any details so far. According to the Ministry of Health and Family Welfare data, so far, 3,281 people have been cured/discharged/migrated since 1 January 2025, and in the last 24 hours, 581 people have been added to the list. The Indian government has asked the States and the Union territories to increase their individual healthcare preparedness to ensure that there is availability of oxygen, ventilators, and essential medicines at hospitals amid COVID-19 comeback concerns, according to an earlier Mint report. 'In view of the recent increase in covid-19 cases in India, a series of technical review meetings were held on 2nd and 3rd June under chairpersonship of Dr Sunita Sharma, director general of health services (DGHS), with representatives of Disaster Management Cell, Emergency Management Response (EMR) Cell, National Centre for Disease Control (NCDC), Indian Council of Medical Research (ICMR), Integrated Disease Surveillance Programme (IDSP) and central government hospitals in Delhi along with representatives from all states and UTs to evaluate the current Covid-19 situation and preparedness measures,' Mint reported citing officials aware of the development. The officials also mentioned that the deaths being reported, the people already had pre-existing illnesses of some sort. The government also has plans to conduct more mock drills to check the nation's preparedness for health facilities, according to the report.
Time of India
2 days ago
- General
- Time of India
With five more deaths, Covid-19 toll rises to 37
NEW DELHI: The death toll due to the current wave of Covid-19 in the country has touched 37, with five fatalities reported Tuesday, which included two from Maharashtra and one each from Kerala, Tamil Nadu and Bengal. Total number of Covid-19 cases has touched 4,026, with Kerala reporting 1,416 cases, followed by Maharashtra (494), Gujarat (397) and Delhi (393). Of the 37 Covid deaths reported in India this year, a maximum of 10 have occurred in Maharashtra, followed by Kerala (9), Delhi (4), Karnataka (4), Tamil Nadu (3) and UP (2). Gujarat, MP, Punjab, Rajasthan and Bengal have reported one death each. Both the persons who died in Maharashtra on Tuesday were women in their 70s with co-morbidities that included diabetes, according to information shared by the govt. The victim in Kerala was an 80-year-old man with severe pneumonia, acute respiratory distress syndrome, diabetes, hypertension and coronary artery disease. The deceased from Tamil Nadu was a 69-year-old woman with type 2 Diabetes Mellitus and Parkinson's Disease, while the one from West Bengal was a 43-year-old woman with co-morbidities that included acute coronary syndrome, septic shock and acute kidney injury.
Business Upturn
3 days ago
- Business
- Business Upturn
Biocon receives CDSCO approval for its Liraglutide drug in India
Biocon Limited, a global biopharmaceutical company, has announced that it has received regulatory approval in India for its Liraglutide drug substance. Its wholly owned subsidiary, Biocon Pharma Limited, has also secured approval for the Liraglutide drug product (6 mg/ml solution for injection in pre-filled pen and cartridge) from the Central Drugs Standard Control Organisation (CDSCO). The product is a generic version of Victoza®, used as an adjunct to diet and exercise to improve glycemic control in adults, adolescents, and children aged 10 years and older with Type 2 Diabetes Mellitus that is not adequately managed. Siddharth Mittal, Chief Executive Officer and Managing Director, Biocon Ltd, commented, 'The approval of our first vertically integrated GLP-1 in India, Liraglutide, is another significant step forward in expanding access of this product to patients suffering from diabetes. India has one of the highest number of people with diabetes globally, with estimates exceeding 77 million cases, and expected to rise further. The approval enables us to address a critical need by making this drug available, and aligns with Biocon's mission to provide affordable, lifesaving medications to those who need it the most. We are now gearing up to launch the product expeditiously through our commercialization partners in India'' This approval was granted under the CDSCO's recently introduced 101 route. This regulatory pathway allows for the recognition of approvals issued by referenced and established foreign regulatory agencies, thereby facilitating faster access to critical medicines in India. Glucagon-like peptide-1 (GLP-1) therapies, including Liraglutide, are being recognized as a growing segment in diabetes management. Biocon has stated its intent to expand its portfolio in this category as part of its future business strategy. Aman Shukla is a post-graduate in mass communication . A media enthusiast who has a strong hold on communication ,content writing and copy writing. Aman is currently working as journalist at
Yahoo
22-05-2025
- Business
- Yahoo
Semaglutide (Ozempic, Wegovy, Rybelsus) Market Trends Analysis and Growth Report 2025-2035: Emerging Markets and Oral Formulations Present New Frontiers for Expansion
The Semaglutide Market, valued at USD 28.43 Billion in 2024, is anticipated to reach USD 93.60 Billion by 2035, growing at a CAGR of 10.47%. Growth drivers include the rising prevalence of diabetes and obesity, regulatory approvals, and expanding clinical indications. Key players like Novo Nordisk lead the market, which is influenced by patent protection and competitive dynamics in drug formulations. Semaglutide Market Dublin, May 22, 2025 (GLOBE NEWSWIRE) -- The "Semaglutide Market Size, Share & Trends Analysis Report by Product (Ozempic, Wegovy, Rybelsus), Application (Type 2 Diabetes Mellitus, Obesity), Route of Administration, Distribution Channel, Region, and Segment Forecasts, 2025 - 2035" report has been added to semaglutide industry is experiencing growth, driven by the increasing prevalence of diabetes and obesity worldwide. The rising demand for glucagon-like peptide-1 receptor agonists (GLP-1 RAs) in diabetes management has positioned semaglutide as a key therapeutic option. The market is influenced by regulatory approvals, expansion in clinical indications, and growing healthcare expenditures that support the adoption of advanced diabetes and obesity treatments. The primary drivers of the market for semaglutide include the increasing burden of type 2 diabetes and obesity, which have escalated the demand for effective therapeutic interventions. The drug's efficacy in reducing cardiovascular risks and aiding weight management has led to expanded usage beyond diabetes treatment. Additionally, favorable reimbursement policies and the growing adoption of self-administered injectable therapies contribute to market growth. Continuous research and development (R&D) activities aimed at improving drug delivery mechanisms further enhance its commercial market presents opportunities for expansion in emerging economies due to rising healthcare infrastructure investments and increasing awareness of diabetes management. There is also potential for further market penetration in obesity treatment, as semaglutide has demonstrated efficacy in weight reduction, leading to regulatory approvals in multiple regions. Pharmaceutical companies are actively exploring novel formulations, including oral versions and combination therapies, to enhance patient compliance and broaden market semaglutide industry is characterized by high R&D investment, stringent regulatory oversight, and strong intellectual property protection. Leading pharmaceutical firms dominate the landscape, leveraging extensive distribution networks and partnerships to expand their market presence. The competitive environment is shaped by ongoing clinical trials, product lifecycle management strategies, and efforts to differentiate products through formulation advancements and expanded is protected by multiple patents that cover its formulation, manufacturing process, and therapeutic applications. The primary patent for semaglutide extends into the 2030s, limiting generic competition and ensuring continued market exclusivity for key manufacturers. Companies investing in alternative formulations, such as oral and extended-release versions, seek additional patent protections to extend commercial viability beyond initial expiration market instances include regulatory approvals for semaglutide in new therapeutic areas, such as obesity treatment, which has significantly expanded its commercial potential. Market leaders have also engaged in strategic collaborations and acquisitions to strengthen distribution capabilities. Additionally, clinical trial results demonstrating superior efficacy compared to existing therapies have reinforced market adoption and driven further investment in next-generation semaglutide industry is poised for sustained growth, supported by increasing diabetes and obesity prevalence, technological advancements in drug delivery, and ongoing R&D initiatives. While patent protections ensure near-term market exclusivity, competitive dynamics may shift as alternative formulations and combination therapies emerge. Industry participants continue to focus on expanding indications and geographic reach to capitalize on the evolving market Market Report Highlights Based on product, Ozempic dominated the market with a revenue share of 59.62% in 2024, driven by strong clinical efficacy, broad regulatory approvals, and increasing adoption for type 2 diabetes. Based on application, Type 2 Diabetes Mellitus dominated the market and accounted for a revenue share of 71.16% in 2024, driven by its rising global prevalence and increasing adoption of advanced therapies. Based on route of administration, parenteral route of administration dominated the market and accounted for a share of 88.46% in 2024, driven by the widespread adoption of Ozempic and Wegovy, both available as injectable formulations. Based on distribution channel, retail pharmacies led the market and accounted for a share of 55.09% in 2024, driven by increasing consumer demand for GLP-1 receptor agonists like Ozempic and Wegovy. Key market players include Novo Nordisk, Eli Lilly, Viking Therapeutics, Lexicon Pharmaceuticals, Biocon, and AstraZeneca. Competition is expected to intensify as biosimilar manufacturers enter the market after semaglutide's patent expires. In March 2025, Novo Nordisk's phase 3b STRIDE trial showed that Ozempic (semaglutide 1.0 mg) improved walking distance by 13% in adults with type 2 diabetes and PAD. Results were presented at ACC 2025 and published in The Lancet. Novo Nordisk has submitted a label extension application to the EMA and FDA. Why Should You Buy This Report? Comprehensive Market Analysis: Gain detailed insights into the market across major regions and segments. Competitive Landscape: Explore the market presence of key players. Future Trends: Discover the pivotal trends and drivers shaping the future of the market. Actionable Recommendations: Utilize insights to uncover new revenue streams and guide strategic business decisions. Company Profiles Novo Nordisk Eli Lilly Viking Therapeutics Lexicon Pharmaceuticals Biocon AstraZeneca Key Attributes: Report Attribute Details No. of Pages 100 Forecast Period 2024 - 2035 Estimated Market Value (USD) in 2024 $28.43 Billion Forecasted Market Value (USD) by 2035 $93.6 Billion Compound Annual Growth Rate 10.4% Regions Covered Global Key Topics Covered: Chapter 1. Methodology and ScopeChapter 2. Executive Summary2.1. Market Snapshot2.2. Segment Snapshot2.3. Competitive Landscape SnapshotChapter 3. Semaglutide Market Variables, Trends, & Scope3.1. Market Lineage Outlook3.2. Market Dynamics3.2.1. Market Driver Analysis3.2.2. Market Restraint Analysis3.3. Business Environment Analysis3.3.1. Industry Analysis - Porter's Five Forces Analysis3.3.2. PESTLE Analysis3.3.3. Pipeline Analysis, by Phase3.3.4. Patent Expiry Analysis3.3.5. Pricing Analysis3.3.6. Competitive Landscape: Emerging Biosimilars in The Post-Patent Semaglutide MarketChapter 4. Semaglutide Market: Product Business Analysis4.1. Product Market Share, 2024 & 20354.2. Product Segment Dashboard4.3. Market Size & Forecasts and Trend Analysis, by Product, 2018 to 2035 (USD Million)4.4. Ozempic4.5. Wegovy4.6. Rybelsus4.7. OthersChapter 5. Semaglutide Market: Application Business Analysis5.1. Application Market Share, 2024 & 20355.2. Application Segment Dashboard5.3. Market Size & Forecasts and Trend Analysis, by Application, 2018 to 2035 (USD Million)5.4. Type 2 Diabetes Mellitus5.5. Obesity5.6. OthersChapter 6. Semaglutide Market: Route of Administration Business Analysis6.1. Route of Administration Market Share, 2024 & 20356.2. Route of Administration Segment Dashboard6.3. Market Size & Forecasts and Trend Analysis, by Route of Administration, 2018 to 2035 (USD Million)6.4. Parenteral6.5. OralChapter 7. Semaglutide Market: Distribution Channel Business Analysis7.1. Distribution Channel Market Share, 2024 & 20357.2. Distribution Channel Segment Dashboard7.3. Market Size & Forecasts and Trend Analysis, by Distribution Channel, 2018 to 2035 (USD Million)7.4. Hospital Pharmacies7.5. Retail Pharmacies7.6. Online PharmaciesChapter 8. Semaglutide Market: Regional Estimates & Trend Analysis8.1. Regional Market Share Analysis, 2024 & 20358.2. Regional Market Dashboard8.3. Market Size & Forecasts Trend AnalysisChapter 9. Competitive Landscape9.1. Participant Overview9.2. Company Market Position Analysis9.3. Company Categorization9.4. Strategy Mapping For more information about this report visit About is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends. Attachment Semaglutide Market CONTACT: CONTACT: Laura Wood,Senior Press Manager press@ For E.S.T Office Hours Call 1-917-300-0470 For U.S./ CAN Toll Free Call 1-800-526-8630 For GMT Office Hours Call +353-1-416-8900Sign in to access your portfolio
NDTV
09-05-2025
- Health
- NDTV
DGT Spain: These Illnesses To Restrict Driving License Renewal; Should India Follow Too?
In a significant effort to improve road safety, Spain's Directorate General of Traffic (DGT) has updated its medical guidelines. These guidelines specify certain health conditions that may disqualify individuals from renewing their driver's licenses. The goal of these measures is to ensure that all drivers have the necessary physical and mental capabilities to operate vehicles safely on public roads. As India faces its own road safety challenges, this development raises a discussion on whether similar measures should be implemented in the nation. In Spain, there are no specific age limits for drivers. Currently, over 4 million licensed drivers are 65 years old or older. The general manager of the DGT has highlighted that psychological and physical examinations will be routinely updated. This process ensures that all drivers, regardless of age, are assessed based on contemporary standards. The DGT has identified several medical conditions that may impair driving abilities. Individuals diagnosed with these conditions could face restrictions or be considered unfit to renew their driving licenses. Key conditions include: Acute Myocardial Infarction Amyotrophic Lateral Sclerosis Automatic Defibrillator Attention Deficit Hyperactivity Disorder (ADHD) Dissection Digestive Diseases Degenerative, Neurological, and Chronic Diseases Dementia or Anxiety Disorder Depression Endocrine Diseases Epilepsy Heart Disease Hypothyroidism and Parathyroid Insulin-Dependent Diabetes Mellitus Intellectual Developmental Disorder Kidney Transplant Neurological Diseases Nephropathy With Dialysis Obsessive-Compulsive Disorder Oncohematic Disorders. Oncological Diseases Pacemaker Parkinson Personality Disorder Respiratory Diseases Sleep Disorders Valve Prostheses Vascular Problems In Spain, all drivers must undergo a medical examination at an authorized Driver Recognition Centre (Centro de Reconocimiento de Conductores) when renewing their licenses. This examination evaluates vision, hearing, coordination, and overall health. Additionally, the DGT (Directorate-General for Traffic) plans to increase the difficulty of psychophysical tests for individuals aged 70 and over. However, in India, the process for renewing a driving license is regulated by the Ministry of Road Transport and Highways. Drivers under 50 years generally do not need a medical exam unless applying for a commercial license but for those over 50 years of age or with specific health issues are required to submit a medical certificate (Form 1A) signed from a registered medical doctor. In India renewing a driving license is regulated by the Ministry of Road Transport and Highways India has one of the highest road accident rates in the world. Implementing stricter health criteria for driving license renewals, similar to Spain's approach, could help reduce accidents due to medical impairments. This would require careful consideration of the country's diverse population and healthcare infrastructure, as well as ensuring access to medical exams and updated health records. Spain's initiative to improve road safety by implementing stringent health-based driving license renewals is something that India could consider. Although the benefits in reducing accidents are apparent, adopting similar measures in India would require a customized approach that addresses the country's unique challenges. A balanced policy that emphasizes both road safety and practical feasibility could lead to safer driving conditions across the nation.
